Skip to main content
Premium Trial:

Request an Annual Quote

ISB Partner Accelerator Corrals $22.5M for Bioscience Start-ups

NEW YORK (GenomeWeb News) - Accelerator, a Seattle-based biotech investment and development organization affiliated with the Institute for Systems Biology, has landed over $22.5 million in financing commitments from several sources.
Accelerator, which formed in 2003 and has helped to raise a total of $130 million for itself and for start-ups, said it will look to use the funds to "identify, evaluate, finance and manage emerging biotechnology opportunities."
Backing for this funding round came from previous investors, including Amgen Ventures, Arch Venture Partners, and OVP Venture Partners. The company said WRF Capital also has committed to chip in financing for Accelerator's projects.
ISB will continue to serve as the “key scientific institutional anchor” for Accelerator.
"ISB has made significant contributions to Accelerator, with half of the first six investments based upon either ISB-based technologies or opportunities identified for Accelerator by ISB faculty," said the Institute's President, Leroy Hood, in a statement.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.